# QLF4113 in Participants With Metastatic Prostate Cancer

> **NCT07636707** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 140 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** QLF4113 for injection

## Key facts

- **NCT ID:** NCT07636707
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-20
- **Primary completion:** 2028-01-05
- **Final completion:** 2028-12-05
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07636707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07636707, "QLF4113 in Participants With Metastatic Prostate Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07636707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*